STMN1 Antibody

1. these data indicate that activation of autophagy reduces expression of STMN1 and p53, and the migration and invasion of cancer cells contributes to the anti-cancer effects of the Halofuginone. These findings may provide new insight into breast cancer prevention and therapy. PMID: 29231257
2. Low expression of STMN1 was found in 43.62%, and high expression of STMN1 was found in 56.38% of cases of osteosarcoma. High tumor expression of STMN1 was a prognostic marker for poor prognosis, poor response to chemotherapy, the presence of metastases, advanced Enneking surgical stage and the chondroblastic osteosarcoma subtype. The expression STMN1 was identified as an independent prognostic biomarker of osteosarcoma . PMID: 30169496
3. a transcription-independent mechanism for Stat3-mediated centrosome clustering that involves Stathmin, a Stat3 interactor involved in microtubule depolymerization, and the mitotic kinase PLK1, is reported. PMID: 28474672
4. Results suggest that stathmin is essential in bipolar spindle formation to maintain genomic stability during mitosis, and the depletion of stathmin prevents the initiation of chromosome instability by inducing senescence in human normal fibroblasts. PMID: 28885720
5. Results showed that STMN1 overexpression was significantly associated with lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma (ESCC) patients. STMN1 levels are regulated by the PI3K pathway, and STMN1 can act as a surrogate marker of PI3K pathway signaling related to tumor recurrence. PMID: 29251330
6. The investigation confirmed that stathmin expression was correlated with more aggressive behavior of cervical cancer. PMID: 29953794
7. High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma. PMID: 28933054
8. STMN1 expression was significantly associated with prognosis and tumour differentiation in ESCC, indicating that STMN1 expression is an independent prognostic factor for ESCC and could be a potential biomarker. Regulating the expression of STMN1 could influence tumour cell motility, invasion and proliferation PMID: 29039594
9. T3-mediated suppression of STMN1 supports the theory that T3 plays an inhibitory role in HCC tumor growth, and suggests that the lack of normal THR function leads to elevated STMN1 expression and malignant growth PMID: 27934948
10. These results suggest that stathmin acts as an oncogene and is transcriptionally regulated by mutant p53, but not by wild-type p53. Stathmin could be a potential anti-tumor therapeutic target in oral squamous cell carcinoma PMID: 28806997
11. Results suggest that Stathmin 1 (STMN1) plays an important role in cell proliferation and migration. PMID: 27349455
12. STMN1 expression was higher in basal-type cell lines than in luminal-type cell lines, and overall survival and post-progression survival in the high STMN1 expression breast cancer patients were shorter than in low STMN1 expression patients. High STMN1 expression is a possible marker of breast cancer aggressiveness in association with proliferation, phenotype and cancer stem cell type PMID: 28766688
13. we found upregulated expression of STMN1 in the atypical/anaplastic meningioma group, relative to that in the benign meningioma group. STMN1, therefore, is a promising target to improve cure rates in meningioma cases. PMID: 28625575
14. An increased risk of sporadic atypical meningioma recurrence can be found in cases with elevated expression of STMN1. PMID: 28622584
15. The miR-34a/STMN1/betaIII-tubulin axis maintains the microtubule cytoskeleton in osteosarcoma, and combining miR-34a with microtubule inhibitors can be investigated as a novel therapeutic strategy. PMID: 28275089
16. These findings suggest that Cdc2 is positively associatd with the development of taxol resistance. The Cdc2 inhibitor, purvalanol A, enhanced the cytotoxic effects of taxol through Op18/stathmin. PMID: 28534969
17. these results showed that stathmin expression was significantly up-regulated in LAC, which may act as a biomarker for LAC. Furthermore, silence of stathmin inhibiting LAC cell growth indicated that stathmin may be a promising molecular target for LAC therapy. PMID: 27494889
18. Increased stathmin correlated with pathologic grade, lymphatic invasion, advanced stage and poor survival of non-small cell lung cancer (NSCLC), which indicated that stathmin could serve as a potential biomarker of NSCLC PMID: 28282798
19. Results showed that patients with cancer displayed a higher stathmin expression than those of non-cancer individuals, and overexpression of stathmin correlated with tumor cell differentiation, lymph node invasion and high TNM stage. [review] PMID: 27806343
20. High STMN1 Expression Is Associated with Tumor Differentiation and Metastasis in Pancreatic Cancer. PMID: 29374725
21. miR-223 might serve as an onco-suppressor that enhances susceptibility to docetaxel by downregulating STMN1 in gallbladder cancer, highlighting its promising therapeutic value. PMID: 27577078
22. overexpression correlates with poorer prognosis and interacts with p53 in oral squamous cell carcinoma PMID: 27591090
23. study elucidated a novel Malat1-miR-101-STMN1/RAB5A/ATG4D regulatory network that Malat1 activates autophagy and promotes cell proliferation by sponging miR-101 and upregulating STMN1, RAB5A and ATG4D expression in glioma cells PMID: 28834690
24. STMN1 gene and miRNA-223 expression profiles in non-tumor liver tissues were predictive of the risk for multicentric hepatocellular carcinoma recurrence. PMID: 28982915
25. The crucial role of FOXM1 and STMN1 in TKI-induced enrichment of CSC and drug resistance was demonstrated by knockdown of STMN1 and FOXM1 in NSCLC cells. PMID: 28850563
26. Our finding demonstrates that RSK2 directly phosphorylates stathmin and regulates microtubule polymerization to provide a pro-invasive and pro-metastatic advantage to cancer cells. Therefore, the RSK2-stathmin pathway represents a promising therapeutic target and a prognostic marker for metastatic human cancers. PMID: 27041561
27. stathmin expression was significantly associated with shorter progression-free survival and overall survival for all analyzed cases of endometrial cancer; findings demonstrate that high stathmin expression is a poor prognostic marker in endometrial cancer PMID: 28532857
28. STMN1 is a possible biomarker for paclitaxel sensitivity and poor prognosis in gastric cancer (GC) and could be a novel therapeutic target in metastatic GC. PMID: 28334732
29. STMN1,COF1 and PAIRBP1 thus represent proteins associated with proliferative and aggressive tumors of high grades, while TSP2 and POSTN were connected to low grade tumors with better prognosis PMID: 28216224
30. The phosphorylation-specific association of STMN1 with GRP78 promotes breast cancer metastasis. PMID: 27130664
31. hese results suggested that STMN1 plays an important role in proliferation and migration of hypopharyngeal squamous cell carcinoma and may be used as a potential prognostic biomarker or therapeutic target of hypopharyngeal squamous cell carcinoma (HSCC) . PMID: 27878293
32. High STMN1 expression is associated with invasion in endometrial carcinoma. PMID: 26815505
33. High expression of stathmin 1 predicts poor outcome in oral squamous cell carcinoma patients treated by docetaxel-containing regimens. PMID: 26590596
34. The expressions of TYMS, TUBB3 and STMN1 were significantly associated with the clinicopathological characteristics of age, gender and family history of gastric cancer, but not with differentiation, growth patterns, metastasis and TNM staging in patients with gastric cancer. PMID: 28056823
35. Stathmin is a highly sensitive and specific biomarker for the diagnosis of vulvar high-grade squamous intraepithelial lesions. PMID: 27226646
36. STMN1 silencing by siRNA may enhance the sensitivity of esophageal cancer cells Eca-109 to paclitaxel and induce apoptosis. PMID: 26782519
37. SNP in STMN1 gene may have a potential predictive role in taxane-based chemotherapy in advanced non-small cell lung cancer. PMID: 26148901
38. After silencing stathmin-1 in gastric cancer cells, the resistance index was reduced. PMID: 26802649
39. Results show that the STMN1-E/P/C signature is a reliable prognostic indicator for luminal subtype breast cancer and may predict the therapeutic response to paclitaxel-based treatments, potentially facilitating individualized management. PMID: 26087399
40. STMN1 may play an important role in the development and tumor progression of cutaneous squamous cell carcinoma PMID: 26235036
41. Studies indicate that phosphorylation of stathmin controls its biological activity by reducing its affinity for tubulin and hence preventing microtubule disassembly. PMID: 26450904
42. FANCC interacts and co-localizes with STMN1 at centrosomes during mitosis. We also showed that FANCC is required for STMN1 phosphorylation. PMID: 26466335
43. PDAC patients with higher STMN1 expression died sooner than those with lower STMN1 expression. PMID: 25791566
44. stathmin-1 may play a key role in regulating trophoblast invasion PMID: 26272359
45. These results suggest that SEPTIN2-mediated cytoskeletal rearrangement and STATHMIN-mediated differentiation may contribute to changes in cell morphology and differentiation of H/RS cells with CD99 upregulation in Hodgkin lymphoma. PMID: 26000982
46. miR-223 regulates STMN1 in malignant pleural mesothelioma, and both are in turn regulated by the JNK signaling pathway. As such, miR-223 and STMN1 play an important role in regulating MPM cell motility. PMID: 25824152
47. Report that STMN1 is a highly sensitive marker for leiomyosarcoma but is suboptimally specific for diagnostic purposes. PMID: 26045786
48. MiR-101 sensitizes human nasopharyngeal carcinoma cells to radiation by targeting stathmin 1 PMID: 25607713
49. High level of stathmin exhibited poor response to chemotherapy (for mRNA, P = 0.041; for protein, P = 0.017). Overexpression of stathmin was associated with shorter overall survival (for mRNA, P = 0.012) and progression-free survival PMID: 25894372
50. STMN1 overexpression is associated with drug resistance in esophageal squamous cell carcinoma. PMID: 25944168

Show More

Hide All

HGNC: 6510

OMIM: 151442

KEGG: hsa:3925

STRING: 9606.ENSP00000410452

UniGene: Hs.209983